Vaxart is a clinical‑stage company developing oral recombinant, temperature‑stable tablet vaccines using a proprietary delivery platform. The platform is suitable for delivering protein antigens used in marketed vaccines and aims to eliminate needles while reducing cold‑chain requirements. The company plans to advance its seasonal influenza tablet vaccine and significantly expand its clinical pipeline beyond influenza. Vaxart expects to conduct phase 1 studies for Ebola and norovirus in 2015; its Ebola tablet vaccine was on schedule to enter the clinic this quarter. Its RSV tablet candidate and a therapeutic tablet vaccine for herpes simplex 2 are currently in preclinical testing. The company reported positive phase 1 safety and immunogenicity results with its H1N1 seasonal influenza tablet vaccine, providing momentum for the planned expansions. Vaxart is a San Francisco biotech developing oral-delivery vaccines formulated to be effective when swallowed in a pill or capsule. Its vaccines incorporate a proprietary adjuvant that boosts the immune response to enable oral administration. The company’s lead product is an oral vaccine for Avian influenza. Vaxart plans to advance that lead candidate through Phase I clinical trials. To support those plans it closed a $12.5M Series B financing. As part of the financing, Richard Markham and Jan Leschly of Care Capital joined Vaxart’s board.

Total raised

$31M

Funding rounds

2

Latest round

Convertible Note

Latest activity

Jan 2015